Inspira Technologies OXY together with Ennocure MedTech announced results from their collaborative development of a proprietary bio-electronic treatment to prevent associated bloodstream infections in patients in intensive care units. Once developed, Inspira plans to integrate the bio-electronic novel physical stimulation technology, into the INSPIRA ART patient treatment. The results of the in vitro study showed a 75% reduction in bacterial growth 4 hours after the application of the treatment and a 100% reduction within 24 hours. The in vitro study was carried out at the Hebrew University of Jerusalem and involved testing bioelectric patches in an in vitro environment. As part of the in vitro study, bacteria were cultured and spread on agar in petri dishes. The bioelectric patch was then applied to the agar plate and activated for a pre-specified duration. Following the procedure, the agar plates were transferred to an incubation chamber for 24 hours and thereafter examined. This technology is based on the use of electrical pulses that inhibit bacterial proliferation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IINN:
- Inspira Technologies Shareholders Approve Agenda
- Inspira Technologies Innovates Neonatal Respiratory Support
- Inspira Technologies begins program to explore use of Inspira device as womb
- Inspira Technologies Completes Share Offering
- Inspira Technologies to sell 1.34M shares at $1.232 in registered direct offer